Clinical Trial Update: Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly [Phase 2]

View source ↗

Summary

Phase 2 study sponsored by Bristol-Myers Squibb in Japanese patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myelofibrosis Post-essential Thrombocythemia
• Myelofibrosis Post-polycythemia Vera

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Myelofibrosis | Phase 2 | Status: COMPLETED